Experienced and Highly Focused Management Team

The XORTX team of multi-disciplinary industry professionals is capable of drug development from discovery to marketing approval. Over 60 years of manufacturing, clinical and regulatory drug development experience.

Concept Validating Clinical Trials

Recent human studies have defined a role for chronically increased serum uric acid (SUA) in a disease axis that includes rare-”orphan” diseases, such as autosomal dominant polycystic kidney disease, hereditary hypouricemia, blood pressure, kidney injury, diabetes, and diabetic nephropathy. Stll more recent human studies have shown that decreasing and maintaining lower uric acid levels using..More

Cornerstone Intellectual Property

XORTX Patents and patent applications claim the use of and composition of uric acid lowering agents for the treatment of hypertension, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy and other diseases.

Latest Press Releases

XORTX Submits FDA pre-IND Meeting Documents

● Advancing to a Phase II Clinical Study in Polycystic Kidney Disease ● CALGARY, Alberta, Aug. 13, 2018 (GLOBE NEWSWIRE) —...

XORTX Reports on Annual Special Meeting and Provides Corporate Update

CALGARY, Alberta, June 28, 2018 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE:XRX) (OTCQB:XRTXF), a biopharmaceutical company focused on...

XORTX Announces Filing of FDA pre-IND Meeting Request Letter

CALGARY, Alberta, June 08, 2018 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE:XRX) (OTCQB:XRTXF), a biopharmaceutical company focused...